Filip K Knop
Filip K Knop
Director, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark
Email confirmado em
Citado por
Citado por
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud
Bmj 344, 2012
Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition
RS Kootte, E Levin, J Salojärvi, LP Smits, AV Hartstra, SD Udayappan, ...
Cell metabolism 26 (4), 611-619. e6, 2017
Recovery of gut microbiota of healthy adults following antibiotic exposure
A Palleja, KH Mikkelsen, SK Forslund, A Kashani, KH Allin, T Nielsen, ...
Nature microbiology 3 (11), 1255-1265, 2018
Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity
A Vrieze, C Out, S Fuentes, L Jonker, I Reuling, RS Kootte, E Van Nood, ...
Journal of hepatology 60 (4), 824-831, 2014
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ...
Diabetes 56 (8), 1951-1959, 2007
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with …
PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ...
Diabetologia 52, 199-207, 2009
Glucagon-like peptide 1 in health and disease
A Andersen, A Lund, FK Knop, T Vilsbøll
Nature Reviews Endocrinology 14 (7), 390-403, 2018
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop
Diabetes 60 (12), 3103-3109, 2011
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes
JJ Holst, FK Knop, T Vilsbøll, T Krarup, S Madsbad
Diabetes care 34 (Suppl 2), S251, 2011
2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans
KB Hansen, MM Rosenkilde, FK Knop, N Wellner, TA Diep, JF Rehfeld, ...
The Journal of Clinical Endocrinology & Metabolism 96 (9), E1409-E1417, 2011
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
S Calanna, M Christensen, JJ Holst, B Laferrere, LL Gluud, T Vilsbøll, ...
Diabetologia 56, 965-972, 2013
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
KJ Hare, T Vilsbøll, M Asmar, CF Deacon, FK Knop, JJ Holst
Diabetes 59 (7), 1765-1770, 2010
Impaired regulation of the incretin effect in patients with type 2 diabetes
JI Bagger, FK Knop, A Lund, H Vestergaard, JJ Holst, T Vilsbøll
The Journal of Clinical Endocrinology & Metabolism 96 (3), 737-745, 2011
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of …
T Vilsbøll, FK Knop, T Krarup, A Johansen, S Madsbad, S Larsen, ...
The Journal of Clinical Endocrinology & Metabolism 88 (10), 4897-4903, 2003
Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
H Storgaard, LL Gluud, C Bennett, MF Grøndahl, MB Christensen, ...
PloS one 11 (11), e0166125, 2016
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
FK Knop, K Aaboe, T Vilsbøll, A Vølund, JJ Holst, T Krarup, S Madsbad
Diabetes, Obesity and Metabolism 14 (6), 500-510, 2012
Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease
L Niu, PE Geyer, NJ Wewer Albrechtsen, LL Gluud, A Santos, S Doll, ...
Molecular systems biology 15 (3), e8793, 2019
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic iv glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
FK Knop, T Vilsbøll, S Madsbad, JJ Holst, T Krarup
Diabetologia 50, 797-805, 2007
The Nkx6. 1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells
JC Schisler, PB Jensen, DG Taylor, TC Becker, FK Knop, S Takekawa, ...
Proceedings of the National Academy of Sciences 102 (20), 7297-7302, 2005
Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
NJ Wewer Albrechtsen, B Hartmann, S Veedfald, JA Windeløv, ...
Diabetologia 57, 1919-1926, 2014
O sistema não pode efectuar a operação agora. Tente mais tarde.
Artigos 1–20